Trial intelligence / Profile preview

PfSPZ-CVac vs MVA ME-TRAP/ChAd63 ME-TRAP in Malaria-naïve Adults

NCT05441410Phase 2Not yet recruiting

Sponsor: University Hospital Tübingen
Start: Jun 2025
Primary completion: Jun 2026
Modality: Viral Vector Vaccines, DNA Vaccines, Live Biotherapeutic Products

Overview

Phase 2, randomised, double-blind trial of PfSPZ Challenge, MVA ME-TRAP and ChAd63 ME-TRAP in malaria (3 arms), sponsored by University Hospital Tübingen. Primary endpoint: Assessment of safety and tolerability of PfSPZ-CVac/Pyramax and MVA ME-TRAP/ChAd63 ME-TRAP. Planned start Jun 2025; status: not yet recruiting.

Drugs

PfSPZ ChallengeMVA ME-TRAPChAd63 ME-TRAP

Conditions

malaria

Beyond the preview

Go deeper on NCT05441410.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT05441410.